Keith Hoffman, former senior vice-president of business development and tech transfer at Lundquist Institute, has joined UCLA spinout Athos Therapeutics.
Lundquist Institute for Biomedical Innovation, an affiliate of University of California, Los Angeles (UCLA), has lost its senior vice-president of business development and tech transfer Keith Hoffman.
Hoffman has left to become chief business officer at UCLA-founded precision therapy developer Athos Therapeutics, where he will be tasked with business development, funding and partnerships.
Lundquist promoted Hoffman to senior vice-president in January this year after his three and a half-year tenure as vice-president for business development and tech transfer, during which he is credited with launching a new incubator for biotech startups.
Before joining the institute, Hoffman was vice-president of health informatics provider Advera Health Analytics from 2010 until 2016.
Athos Therapeutics’ founding team includes Michael Jung, a professor of chemistry at UCLA’s Department of Chemistry and Biochemistry.
The spinout’s lead program targets inflammatory bowel disease, and it is also progressing candidates for autoimmune diseases and cancer.
– Image courtesy of Lundquist Institute
